David L Hava (David Hava)

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 14

Top Venues

PloS one

ACS synthetic biology

British journal of clinical pharmacology

Clinical cancer research : an official journal of the American Association for Cancer Research

Tufts Graduate School of Biomedical Sciences (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

Tufts Graduate School of Biomedical Sciences

United States

PHD :: Molecular Biology and Microbiology

Publications

David Lubkowicz, David L Hava, Kim Lewis, Vincent M Isabella
Rational Engineering of Escherichia coli Nissle 1917 as Live Biotherapeutic to Degrade Uremic Toxin Precursors. ACS synthetic biology 13 (4) (2024)
David Lubkowicz, David L Hava, Kim Lewis, Vincent M Isabella
Rational Engineering of Escherichia coli Nissle 1917 as Live Biotherapeutic to Degrade Uremic Toxin Precursors. ACS synthetic biology 13 (4) (2024)
David Lubkowicz, David L Hava, Kim Lewis, Vincent M Isabella
Rational Engineering of Escherichia coli Nissle 1917 as Live Biotherapeutic to Degrade Uremic Toxin Precursors. ACS synthetic biology 13 (4) (2024)
David Lubkowicz, David L Hava, Kim Lewis, Vincent M Isabella
Rational Engineering of Escherichia coli Nissle 1917 as Live Biotherapeutic to Degrade Uremic Toxin Precursors. ACS synthetic biology (2024)
Liliana M Sanmarco, Joseph M Rone, Carolina Manganeli Polonio, Gonzalo Fernandez Lahore, Federico Giovannoni, Kylynne Ferrara, Cristina Gutiérrez-Vázquez, Ning Li, Anna Sokolovska, Agustin Plasencia, Camilo Faust Akl, Payal Nanda, Evelin S Heck, Zhaorong Li, Hong-Gyun Lee, Chun-Cheih Chao, Claudia M Rejano-Gordillo, Pedro H Fonseca-Castro, Tomer Illouz, Mathias Linnerbauer, Jessica E Kenison, Rocky M Barilla, Daniel Farrenkopf, Nikolas A Stevens, Gavin Piester, Elizabeth N Chung, Lucas Dailey, Vijay K Kuchroo, David L Hava, Michael A Wheeler, Andrew T Chan, Roni Nowarski, Eduardo Balsa, Jose M Lora, Francisco J Quintana
Lactate limits CNS autoimmunity by stabilizing HIF-1α in dendritic cells. Nature (2023)
Aida Kalantari, Michael J James, Lauren A Renaud, Mylene Perreault, Catherine E Monahan, Mary N McDonald, David L Hava, Vincent M Isabella
Robust performance of a live bacterial therapeutic chassis lacking the colibactin gene cluster. PloS one 18 (2) (2023)
Jason John Luke, Sarina A Piha-Paul, Theresa M Medina, Claire F Verschraegen, Mary Varterasian, Aoife M Brennan, Richard J Riese, Anna Sokolovska, James F Strauss, David L Hava, Filip Janku
Phase I study of SYNB1891, an engineered E coli Nissle strain expressing STING agonist, with and without atezolizumab in advanced malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Jason John Luke, Sarina A Piha-Paul, Theresa M Medina, Claire F Verschraegen, Mary Varterasian, Aoife M Brennan, Richard J Riese, Anna Sokolovska, James F Strauss, David L Hava, Filip Janku
Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Aida Kalantari, Michael J James, Lauren A Renaud, Mylene Perreault, Catherine E Monahan, Mary N McDonald, David L Hava, Vincent M Isabella
Robust performance of a live bacterial therapeutic chassis lacking the colibactin gene cluster. PloS one 18 (2) (2023)
Aida Kalantari, Michael J James, Lauren A Renaud, Mylene Perreault, Catherine E Monahan, Mary N McDonald, David L Hava, Vincent M Isabella
Robust performance of a live bacterial therapeutic chassis lacking the colibactin gene cluster. PloS one 18 (2) (2023)
Aida Kalantari, Michael J James, Lauren A Renaud, Mylene Perreault, Catherine E Monahan, Mary N McDonald, David L Hava, Vincent M Isabella
Robust performance of a live bacterial therapeutic chassis lacking the colibactin gene cluster. PloS one 18 (2) (2023)
David Lubkowicz, Nicholas G Horvath, Michael J James, Pasquale Cantarella, Lauren Renaud, Christopher G Bergeron, Ron B Shmueli, Cami Anderson, Jian-Rong Gao, Caroline B Kurtz, Mylene Perreault, Mark R Charbonneau, Vincent M Isabella, David L Hava
An engineered bacterial therapeutic lowers urinary oxalate in preclinical models and in silico simulations of enteric hyperoxaluria. Molecular systems biology 18 (3) (2022)
David L Hava, Lisa Tan, Patrick Johnson, Aidan K Curran, Jason Perry, Steve Kramer, Katie Kane, Pauline Bedwell, Gary Layton, Clarie Swann, Dennis Henderson, Naimat Khan, Lucy Connor, Litza McKenzie, Dave Singh, James Roach
A phase 1/1b study of PUR1900, an inhaled formulation of itraconazole, in healthy volunteers and asthmatics to study safety, tolerability and pharmacokinetics. British journal of clinical pharmacology 86 (4) (2020)
Jason Perry, Brian Trautman, Joe Takher-Smith, Steve Kramer, Katie Kane, Michael Silverman, Lisa Tan, Scott Haughie, Wolfram Richter, Valentin Kirkov, Sacha Arsova, Jonathan Ward, David L Hava
Particle size and gastrointestinal absorption influence tiotropium pharmacokinetics: a pilot bioequivalence study of PUR0200 and Spiriva HandiHaler. British journal of clinical pharmacology 85 (3) (2019)

David L Hava.css-eqlu8i{font-size:small;padding-left:4px;} (David Hava)

Publication Activity (10 Years)

Top Topics

Top Venues

David L Hava (David Hava)